Lukasz Biernat

LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY

Evan A. Stein, Sreeneeranj Kasichayanula, Traci Turner et al. · Journal of the American College of Cardiology · 2014 · 48 citations

Lipid Disorder, Oxysterol, Cardiovascular Disease +8

Drug-induced liver damage -- a three-year study of patients from one gastroenterological department.

Marek Hartleb, Lukasz Biernat, Anna Kochel · PubMed · 2002 · 47 citations

Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers

David C. Rice, Justin W. Heil, Lukasz Biernat · Clinical Drug Investigation · 2017 · 26 citations

Liposomal Bupivacaine, Pharmacokinetic Profile, Pharmacology +6

Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

Corby K. Martin, Owen Carmichael, Susan Carnell et al. · Nature Medicine · 2025 · 20 citations · Full text

LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY

Evan A. Stein, Traci Turner, Lukasz Biernat et al. · Journal of the American College of Cardiology · 2019 · 12 citations

Lipid Disorder, Cardiovascular Disease, A Randomized +7